Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Disease Progression × Ifosfamide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Sarcoma 2 Neuroectodermal Tumors, Primitive, Peripheral 2 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma 2 Neoplasms 1 Lymphoma, Non-Hodgkin 1 Hodgkin Disease 1 Disease Progression 1

Interventions

grapiprant 1 fludarabine 1 famitinib 1 camrelizumab 1 TPI-287 1 Lycopene 1 Ifosfamide 1 Gemcitabine 1 Cyclophosphamide 1 3-fluoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04044378 2020-05-19

Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma

Peking University People's Hospital

Phase 1/2 Withdrawn

Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon ⚡